ResMed Shares Decline Despite Strong Business Performance
ResMed shares have come under pressure in recent weeks, surprising investors who have long viewed the company as one of the most stable performers in the healthcare sector. The stock declined for five consecutive trading sessions through mid-March 2026, falling about 8.8% and erasing roughly $3.3 billion from its market value.
As of March 18, 2026, ResMed is trading at $231, significantly below its 52-week high of $293. This decline has created uncertainty among investors, particularly because it comes without any major deterioration in the company’s core business performance.
ResMed shares have declined in recent sessions, reflecting market uncertainty despite strong fundamentals. [TradingView]
The selloff has raised an important question for those considering a ResMed shares investment. Is the recent weakness a signal of deeper issues, or does it represent a temporary disconnect between market sentiment and strong fundamentals?
Why the Recent Selloff Matters to Investors
The current situation is important for investors, especially those focused on long-term healthcare trends and medical device stocks. ResMed operates in a sector driven by structural demand rather than short-term economic cycles, making it relevant for portfolio stability.
The ageing population healthcare demand is one of the most powerful long-term themes globally. As populations grow older, the prevalence of respiratory conditions such as sleep apnea and COPD increases, directly supporting demand for ResMed’s products.
The global respiratory care devices market is set to grow from $26.76 billion in 2025 to $62.64 billion by 2035, a market in which ResMed is uniquely positioned to dominate. (Source: Precedence Research)
For investors, this creates a key opportunity to evaluate whether the current dip in share price offers an attractive entry point. If the company’s growth drivers remain intact, short-term volatility may present long-term value.
ResMed’s Position in the Global Medical Device Market
ResMed Inc. is a global medical device company headquartered in San Diego, operating in more than 140 countries. It focuses on developing solutions for sleep apnea, chronic respiratory diseases, and digital health management.
The company generates revenue across three main segments:
- Devices such as CPAP and ventilation systems
- Masks and accessories that provide recurring income
- Residential care software, which now contributes the largest share of revenue
ResMed CPAP devices are widely used to treat sleep apnea and respiratory conditions worldwide. [Respiratory Therapy]
This strong mix of hardware and software gives ResMed a competitive advantage within medical device stocks. Its increasing reliance on recurring software revenue also supports more predictable earnings over time.
Global Demand Driven by Ageing Population Trends
ResMed’s growth is closely tied to demographic trends. The global population aged 60 and above is expected to rise significantly over the coming decades, increasing the prevalence of sleep-related and respiratory conditions.
This trend is not cyclical and is unlikely to reverse. As a result, ageing population healthcare demand continues to expand ResMed’s addressable market each year.
In addition, awareness of sleep health is rising, but a large portion of affected individuals remain undiagnosed or untreated. This gap between awareness and treatment creates long-term growth potential for the company.
Recent Financial Performance Signals Business Strength
Despite the recent share price decline, ResMed’s financial performance remains strong. In its Q2 FY2026 results, the company reported revenue of $1.42 billion, representing an 11% year-on-year increase.
Margins also improved, with gross margin exceeding 61% and earnings per share showing solid growth. These figures suggest that the company continues to operate efficiently and expand profitability.
Management has reaffirmed its full-year guidance and increased share buybacks to over $600 million. Such actions typically indicate confidence in the company’s financial position and future growth.
Rising Costs and Operational Concerns to Monitor
While overall performance remains strong, certain cost-related factors warrant attention. Selling, general, and administrative expenses have grown faster than revenue, partly due to acquisitions and ongoing investments in technology.
These rising costs may put pressure on margins in the short term, even though they are intended to support long-term growth. Investors will likely monitor how efficiently these investments translate into revenue expansion.
The upcoming Q3 FY2026 earnings report is expected to provide further clarity on cost management and operational efficiency.
ResMed Stock Outlook and Analyst Expectations
Analyst sentiment toward ResMed remains largely positive despite the recent decline. The average 12-month price target is close to $297, indicating potential upside from current levels.
Most analysts maintain a buy rating, supported by strong margins and consistent earnings growth. These indicators suggest that the underlying business remains healthy and continues to perform well relative to expectations.
However, some concerns remain around growth guidance, which has been adjusted to a more moderate pace. This has contributed to cautious sentiment among certain investors.
Key Risks Facing ResMed Shares Investment
No investment is without risk, and ResMed is no exception. Several factors could influence its future performance:
- Currency fluctuations due to its global operations
- Rising operational costs linked to acquisitions and technology spending
- Competitive pressure within the medical device sector
- Technical indicators suggesting short-term market weakness
There is also ongoing discussion about the potential impact of weight-loss drugs on sleep apnea rates. While this remains a consideration, many analysts believe the long-term impact may be limited.
Future Outlook and Growth Drivers
Looking ahead, ResMed’s growth will likely be driven by a combination of demographic trends, technological innovation, and expanding digital health solutions.
The company’s focus on AI-powered devices and cloud-based platforms positions it well within the broader shift toward connected healthcare. These innovations could enhance patient outcomes while creating additional revenue streams.
As the ageing population’s healthcare demand continues to rise, ResMed remains well-positioned to benefit from long-term structural growth.
Also Read: Resolution Minerals 45-Hole Drilling Campaign at Golden GateÂ
ResMed Shares Investment Outlook for 2026
ResMed’s recent share price decline reflects short-term market sentiment rather than a clear deterioration in fundamentals. The company continues to generate strong revenue, expand margins, and invest in future growth.
For long-term investors, the current price level may represent an opportunity to enter a business aligned with powerful demographic trends. However, near-term volatility and upcoming earnings results could continue to influence performance.
Overall, the ResMed stock outlook remains balanced, with strong fundamentals supporting long-term growth, while short-term risks require careful monitoring.
FAQS
- What is driving the recent decline in ResMed shares?
Ans. The recent decline is mainly linked to market sentiment, moderate growth guidance, and rising operating costs rather than any major weakness in ResMed’s core business performance.
- Is ResMed a good long-term investment?
Ans. ResMed is considered a strong long-term investment due to its position in the growing sleep and respiratory care market, supported by the ageing population’s healthcare demand.
- How does the ageing population impact ResMed’s growth?
Ans. An ageing global population increases the prevalence of sleep apnea and respiratory conditions, directly boosting demand for ResMed’s devices and digital health solutions.
- What are the main risks for the investment in ResMed shares?
Ans. Key risks include rising operational costs, currency fluctuations, competition in the medical device sector, and short-term technical weakness in the stock.
- What is the outlook for ResMed stock in 2026?
Ans. The ResMed stock outlook remains positive, with analysts expecting potential upside driven by strong earnings, recurring revenue growth, and expanding global demand.
Disclaimer:Â
This article is intended for informational and educational purposes only. It does not constitute financial or investment advice. Past performance is not indicative of future results. Always consult a licensed financial adviser before making investment decisions.
Sources
https://tickernerd.com/stock/rmd-forecast/Â
https://pmc.ncbi.nlm.nih.gov/articles/PMC12428043/Â
https://finance.yahoo.com/quote/RSMDF/Â
https://www.macrotrends.net/stocks/charts/RMD/resmed/stock-price-historyÂ
https://robinhood.com/us/en/stocks/RMD/Â
https://www.precedenceresearch.com/respiratory-care-device-marketÂ
Last modified: March 19, 2026
